Top

BY Clayton Boldt, Ph. D.

MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches to our patients quickly, safely and effectively. The platform is one of the research engines driving MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives. 

By working closely...

Katy Rezvani, M.D., Ph.D., equips innate immune system natural killer cells with a chimeric antigen receptor that targets B cell malignancies, an approach that’s yielded results in early clinical trials. Her lab is developing CAR NK cells against other cancers.

BY Andrew Olin

A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to research the use of modified immune cells to fight...

BY Ron Gilmore

Cell-based immunotherapies such as chimeric antigen receptors (CAR T), T-cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes...